New obesity drug eloralintide tested in chinese volunteers
NCT ID NCT06916091
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a single dose of the investigational drug eloralintide in 30 Chinese adults who are overweight or have obesity. The main goal was to check safety and side effects, and to measure how the drug moves through the body. Participants were randomly assigned to receive either the drug or a placebo injection under the skin.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
30 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Chinese participants. To qualify as Chinese, all 4 of the participant's biological grandparents must be of exclusive Chinese descent and born in China * Have had a stable body weight for 3 months prior to screening. Participants with body weight change of less than 5% will be allowed * Have not modified diet or adopted any nutritional lifestyle modification for 3 months before randomization * Have clinical laboratory test results within a normal range for the population or investigative site at screening and lead-in, or results with acceptable deviations that are judged to be not clinically significant by the investigator * Have a body mass index (BMI) within the range 27 to 40 kilogram per square meter (kg/m²) Exclusion Criteria: * Are pregnant, or intend to become pregnant or to breastfeed during the study * Have known allergies to related compounds of eloralintide * Have any of the following abnormal blood pressure (BP) and/or pulse rate at screening, constituting a risk when taking the investigational product with minor deviations judged to be acceptable by the investigator: * Supine BP \> 160/90 millimeter mercury (mmHg) * Supine pulse rate \< 50 or \> 100 beats per minute (bpm) * Orthostatic hypotension * Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs * Regularly use known drugs of abuse and/or show positive findings on drug screening that are not consistent with the medical history or concomitant medication history * Have donated blood of more than 450 mL within the previous 3 months of study screening, or intend to donate blood during the course of the study * Have a history of chronic medical conditions involving the heart, liver, or kidneys * Have a medical history or current evidence of clinically significant cardiac condition
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Obesity are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lilly Centre for Clinical Pharmacology
Singapore, 138623, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which exercise dose best helps kids with metabolic syndrome?
- Custom knee guides put to the test in obese patients
- A pill for obesity? early human trial puts MDR-001 to the test
- Can a weekly shot help people who still struggle with weight after bariatric surgery?
- Do GLP-1 Weight-Loss drugs change how teens eat and feel?
- Can electrical muscle stimulation boost exercise benefits after menopause?